Novavax
NVAX
215 hedge funds and large institutions have $422M invested in Novavax in 2023 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 66 increasing their positions, 48 reducing their positions, and 39 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 48
1% more capital invested
Capital invested by funds: $417M → $422M (+$5.61M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 222 → 215 (-7)
3.93% less ownership
Funds ownership: 69.75% → 65.82% (-3.9%)
15% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 39
23% less call options, than puts
Call options by funds: $67.4M | Put options by funds: $87.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.5M |
| 2 |
SCM
Shah Capital Management
Raleigh,
North Carolina
|
+$9.67M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.54M |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$3.98M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$24.4M |
| 2 |
Citigroup
New York
|
-$9.74M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
-$6.64M |
| 4 |
Coatue Management
New York
|
-$5.72M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$4.85M |
NVAX Hedge Fund Activity: Q2 2023 in Review
215 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q2 2023, worth a combined $422M — up 1.3% from $417M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of NVAX and 33 opened new positions — a net loss of 6 holders — while 48 trimmed existing stakes and 66 added.
The largest buyer was BlackRock, adding an estimated $17.5M. The largest seller was Renaissance Technologies, cutting an estimated $24.4M.
- 215 institutional investors held Novavax (NVAX) as of Q2 2023, down from 222 in Q1 2023.
- Funds reported $422M of Novavax stock for Q2 2023, up 1.3% quarter-over-quarter.
- 33 funds opened new Novavax positions in Q2 2023 and 39 closed out, a net change of -6 holders.
- The largest Novavax buyer in Q2 2023 was BlackRock, an estimated $17.5M added.
- The largest Novavax seller in Q2 2023 was Renaissance Technologies, an estimated $24.4M sold.
Based on aggregated 13F filings for Q2 2023.